Frontlight ResearchEarly access
Active, not recruitingNo phase
Beating Heart Mitral Valve Repair With the HARPOON™ System
Key facts
- Who runs it
- Edwards Lifesciences
- Where
- Ann Arbor, Atlanta, Baltimore, Murray, Nashville, Portland, Rochester, and San Francisco, United StatesSee the 9 sites
- Trial code
- Status
- Active, not recruiting
- People taking part
- 25 people enrolled
- Started
- 16 Dec 2020
- Expected to end
- 20 Dec 2027
- Type of study
- Interventional
- Treatments tested
- HARPOON™ Beating Heart Mitral Valve Repair System
- Record updated
- 19 August 2026
Who can take part
- Age
- 21 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (40)Hide the full registry criteria
Who can take part
- Each subject is required to meet all of the following inclusion criteria:
- Patient is >/= 21 years old
- Presence of severe degenerative mitral regurgitation with mid-segment posterior leaflet prolapse (without commissural involvement) by echocardiographic study
- Mitral leaflet coaptation surface sufficient to reduce mitral regurgitation without undue leaflet tension, based on the judgment of the Echocardiographic Core Lab
- Patient competent to sign informed consent and able to return for follow-up and is capable of participating in all testing associated with this clinical investigation
Who cannot take part
- Have undergone cardiac or peripheral vascular procedures within 30 days prior to the trial procedure
- Requirement for concomitant cardiac surgery
- Previous structural heart intervention (e.g. any heart valve replacement or repair procedures). Previous percutaneous coronary intervention (PCI) is allowed
- Previous coronary artery bypass grafting (CABG)
- Stroke within 30 days prior to index procedure
- ST segment elevation myocardial infarction (STEMI) requiring intervention within 30 days prior to index procedure
- Active SARS-CoV-2 infection (Coronavirus-19 [COVID-19]) or previously diagnosed with COVID-19 with sequelae that could confound endpoint assessments (as assessed by Case Review Committee)
- Planned treatment with any other investigational device or procedure through 1-year follow-up, or who are currently participating in an investigational drug or device trial
- Concurrent medical condition with a life expectancy of less than 12 months in the judgment of the Investigator
- Planned cardiac or peripheral vascular procedures within 30 days after the trial procedure
- Severe pulmonary hypertension (pulmonary artery systolic pressure > 60mmHg)
- Severe aortic stenosis or insufficiency
- Any history of endocarditis
- Contraindication to cardiac surgery, including hostile chest or history of mediastinal radiation
- Evidence of cirrhosis or hepatic synthetic failure (Child-Pugh Class B or higher, [or MELD score of ≥ 13])
- Rheumatic heart disease including rheumatic mitral stenosis
- Condition or conditions that, in the opinion of the Investigator, precludes participation, including willingness to comply with all follow-up procedures
- Contraindication for transesophageal echocardiography (TEE), including esophageal spasm, esophageal stricture, esophageal laceration, esophageal perforation, esophageal diverticula (e.g. Zenker's diverticulum)
- Left ventricular ejection fraction (LVEF) <30%, or severely impaired right ventricular dysfunction as measured by the core lab
- Renal insufficiency CKD Stage 3b or worse (GFR < 45 ml/min/1.73 m2)
- History of bleeding diathesis or coagulopathy or leukopenia (WBC < 3000 mcL) or acute anemia (Hb < 9 g/dL) or thrombocytopenia (platelets < 50,000 cells mcL)
- Pregnant or lactating at the time of enrollment (women of childbearing age should have negative pregnancy test within 72 hours of surgery) or planning pregnancy within the next 12 months
- Patients will be excluded if ANY of the following criteria apply:
- Functional mitral regurgitation (FMR)
- Evidence of anterior or bileaflet prolapse
- Severe mitral annular calcification (MAC)
- Moderate or greater leaflet calcification
- Fragile or thinning apex (e.g. LV aneurysm)
- Severe tricuspid regurgitation. (Patients with mild or moderate tricuspid regurgitation are not excluded.)
- Hemodynamic instability or cardiogenic shock at the time of enrollment (e.g. requiring inotropic support or mechanical support devices)
- Refuse blood products
- Carotid stenosis ≥ to 80% at time of enrollment
- Echocardiographic evidence of intracardiac mass (e.g. left ventricular, atrial, or appendage thrombus, myxoma, or vegetation)
- Cannot tolerate procedural anticoagulation or post-procedure antiplatelet regimen; Intra-operative exclusion criteria
- No longer meets eligibility criteria based on intra-operative assessment
Where in United States
- University of Michigan Health SystemAnn Arbor, United States
- Piedmont Heart InstituteAtlanta, United States
- Johns HopkinsBaltimore, United States
- University of Maryland Medical CenterBaltimore, United States
- Intermountain Heart InstituteMurray, United States
- Centennial Medical CenterNashville, United States
- OHSU Knight Cardiovascular InstitutePortland, United States
- Mayo ClinicRochester, United States
- UCSFSan Francisco, United States
About the trial
What the trial wants to find out
The objective of the study is to evaluate the safety and effectiveness of the HARPOON™ System in the treatment of patients with severe degenerative mitral regurgitation (DMR).
The group in the trial
- HARPOON™ Beating Heart Mitral Valve Repair SystemTreatment being tested
Subjects who were treated with the HARPOON™ Beating Heart Mitral Valve Repair System
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Prospective, Multi-center Trial to Evaluate the Safety and Effectiveness of Beating Heart Mitral Valve Repair With the HARPOON™ System (RESTORE)
- Record updated
- 19 August 2026